Categories: News

TrialAssure Amplifies Clinical Trial Transparency Functionality with the Release of REGISTRY 2.5

CANTON, Mich., April 17, 2019 /PRNewswire/ — TrialAssure® – a leading, global software company focused on developing clinical trial transparency tools – announced today the launch of TrialAssure REGISTRY 2.5, the latest iteration of TrialAssure’s premiere clinical trial registration and disclosure reporting application with a configurable workflow engine that allows clients to augment regulatory intelligence for global registries.

The three main new features in REGISTRY 2.5 include:

  • an improved, more customizable Workflow Management Hub,
  • enhanced alignment to global registry changes, and
  • smarter alerts for delinquency findings – all designed to keep sponsors on track and meet sensitive deadlines.

“From design to development, sponsor input has inspired TrialAssure REGISTRY 2.5,” said Mohamad Zahreddine, CIO, TrialAssure and member of the Forbes Technology Council. “We consistently seek sponsor feedback to improve all facets of our software. Since sponsors use the product daily, they have unique perspectives and suggestions for strengthening even the smallest functionality, and TrialAssure employs a flexible operating model with in-house developers that makes implementing changes quick and easy.”

A smarter application

TrialAssure REGISTRY 2.5 is a smarter application that auto-calculates workflow steps based on project progress. If a user completes a step earlier or later than anticipated, REGISTRY 2.5 will adjust the remaining due dates accordingly. If a user is off-track, the new delinquency finding feature sends a warning about the study’s progress and approaching deadlines.

Workflows are now fully configurable, meaning users can create an unlimited number of workflow steps. Workflows – and the expected durations for each step – can be tailored to specific business units, products, or even individual studies. Using customizable templates, REGISTRY 2.5 users can create a workflow that suits their needs and allows for adjustments over the course of a study.

Additionally, REGISTRY 2.5 includes enhanced registry integrations and modernized validation rules. With these new features, TrialAssure expands reviewer functionality and efficiency.

“REGISTRY 2.5 is the perfect choice for all sponsors who are looking for a seamless, defined process for registering clinical trials and publishing results,” said Zach Weingarden, Product Solutions Manager, TrialAssure. “We carefully evaluate all sponsor feedback, and we are excited to give the pharmaceutical industry an even stronger transparency application that works best for them.”

Available now

TrialAssure REGISTRY 2.5 is available now, and lets users manage the entire disclosure process from start to finish, including registry assessments, validation and quality checks, review cycles, approvals, and comments from regulatory authorities.

In the next iteration, users can expect heightened performance with a new sleek and modern user interface with the upcoming release of TrialAssure Registry 3.0 this fall.    
Request a free demo at: http://www.trialassure.com/contact-us/

About TrialAssure
TrialAssure is a global clinical trial disclosure and transparency reporting suite with unmatched experience in helping clients navigate complex regulatory submission and reporting challenges. TrialAssure helps meet regulatory compliance goals through a flexible, scalable, and streamlined platform that regularly adapts to ever-changing clinical trial disclosure requirements. Established in 2009, TrialAssure was built from the ground up as a single, integrated transparency system, and it is continually strengthened by the experience of leading pharmaceutical industry compliance experts. For more information, visit: www.trialassure.com.

Media contact
Don McLean
+1-734-245-0165
media@trialassure.com 

View original content:http://www.prnewswire.com/news-releases/trialassure-amplifies-clinical-trial-transparency-functionality-with-the-release-of-registry-2-5–300825542.html

SOURCE TrialAssure

Staff

Recent Posts

NuGen Announces Completion of InsuJet(TM) Training with Sol-Millennium(TM) Brazil

Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

5 hours ago

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. -…

5 hours ago

Replicare Attracts Seasoned Leaders From Surgical Telepresence Space

SAN ANTONIO, July 1, 2024 /PRNewswire/ -- Replicare, a leading innovator in remote surgical telepresence…

5 hours ago

MED-LAB ANNOUNCES NEW NAME, LOOK & BUSINESS EXPANSION

MIAMI, July 1, 2024 /PRNewswire/ -- Med-Lab is excited to announce that it is changing…

5 hours ago

Notice of SysInformation Healthcare Services, LLC Data Security Event Which Affected Atlanta Perinatal Consultants, LLP

ATLANTA, July 1, 2024 /PRNewswire/ -- SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM, is a professional…

5 hours ago

Segmed Unveils New Brand Identity and Introduces Openda, the Next Evolution for Its Insight Platform

Openda: Empowering Healthcare Innovation with Advanced Medical Imaging Data Solutions PALO ALTO, Calif., July 1,…

5 hours ago